- Home
- ANAB vs EOSE Comparison
ANAB vs EOSE Comparison
Compare ANAB & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | EOSE |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | 787 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANAB | EOSE |
|---|---|---|
| Price | $54.57 | $3.84 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 7 |
| Target Price | ★ $71.67 | $9.42 |
| AVG Volume (30 Days) | 723.1K | ★ 26.7M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $172.02 |
| Revenue Next Year | $52.14 | $97.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $3.11 |
| 52 Week High | $73.30 | $19.86 |
Technical Indicators
Market Signals| Indicator | ANAB | EOSE |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 42.45 |
| Support Level | $54.23 | $3.11 |
| Resistance Level | $57.70 | $8.15 |
| Average True Range (ATR) | 3.31 | 0.37 |
| MACD | 0.04 | 0.13 |
| Stochastic Oscillator | 57.04 | 51.31 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector.